[Breaking] Celltrion: "Rekkironaju shows equivalent efficacy against UK variant virus"
![[Breaking] Celltrion: "Rekkironaju shows equivalent efficacy against UK variant virus"](http://www.asiae.co.kr/news/img_view.htm?img=2020120409454047289_1607042740.png)
[Asia Economy Reporter Chunhee Lee] Seo Jung-jin, Honorary Chairman of Celltrion, announced on the 18th that the company will continue to respond to variant viruses in relation to its COVID-19 antibody treatment 'Rekkironaju (CT-P59)'.
On the same day, Chairman Seo held an online press conference and stated that responses to variant viruses spreading domestically and internationally, such as those from the United Kingdom and South Africa, are already underway.
Hot Picks Today
"Now Our Salaries Are 10 Million Won a Month" Record High... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- Experts Already Watching Closely..."Target Price Set at 970,000 Won" Only Upward Momentum Remains [Weekend Money]
- "Heading for 2 Million Won": The Company the Securities Industry Says Not to Doubt [Weekend Money]
- Did Samsung and SK hynix Rise Too Much?... Foreign Assets Grow Despite Selling [Weekend Money]
- "Chanel Open Run? I Get a Free Pass"... The World of the Top 0.1% That Money Alone Can't Enter [Luxury World]
He explained that the evaluation of neutralizing ability against variant viruses showed that Rekkironaju exhibited the same neutralizing ability against the UK variant virus as it did before the mutation.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
